35th Hemophilia Symposium

I..Epidemiology

1. HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2003/2004 Survey)
W. Schramm, H. Krebs

2. Hemophilia Registry of the Medical Committee of the Swiss Hemophilia Association — Update and Annual Survey 2004
S. Hartmann, K. Locher

II..Risk of Infections and Inhibitors in Hemophilia

3. Update on the Safety of Clotting Factors, Mainly Regarding the Risk of Transmission of vCJD (Variant Creutzfeldt Jakob Disease)
L. G. Gürtler

4. nvCJD and Blood Products in the UK
P. L. F. Giangrande

5. Mutation Type Dependent Inhibitor Risk — a Single Center Study on 432 Patients with Severe Hemophilia A
J. Oldenburg, J. Schröder, R. Schwaab, C. Müller-Reible, E. Seifried, P. Hanfland, H.-H. Brackmann

6. Inhibitor Incidence in Previously Untreated Patients (PUPs) with Hemophilia A and B. A Prospective Multi-Center Study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH)
W. Kreuz, G. Auerswald, U. Budde, H. J. Klose, H. Lenk

7. ADVATE Inhibitor Risk Profile: 18 Months post-Licensure
E. Gomperts

8. EACH-Registry: An European Registry for Acquired Hemophilia
A. Huth-Kühne, P. Lages, R. Fischer, R. Zimmermann

9. Elective Orthopedic Surgery for Hemophilia Patients with Inhibitors
P. L. F. Giangrande

III..Chronic Synovitis and Long-term Results of Orthopedic Treatment

10. Results after Total Knee and Hip Replacement in Patients with Hemophilia A — A Single Center Experience
R. Klamroth, Ch. Heinrichs, S. Gottstein, R. Koch

11. Motion Analysis Epidemiology in Hemophilic Children
A. Seuser, G. Schumpe, T. Wallny, H.-H. Brackmann

12. Radiosynoviorthesis in Hemophilic Arthropathy — A Single Center Experience
S. Gottstein, R. Klamroth

IV..Laboratory Diagnostics: Coagulation Factor, Inhibitors, Monitoring

13. Individual Therapy of Hemophilia — New Laboratory Methods Considering Platelets
Th. Siegemund, A. Siegemund, S. Bassus, W. Wegert, S. Petros, U. Scholz, L. Engelmann

14. Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Reveals Conformational Epitopes on FVIII and Identifies Small Molecules Blocking Inhibitor and Targeting B Cells
C. Kessel, C. Königs, R. Linde, C. Escuriola-Ettingshausen, J. Roland, H. Stoll, T. Klingebiel, U. Dietrich, W. Kreuz

15. Lack of Factor VIII Expression Represents a Novel Mechanism Leading to Hemophilia A
O. El-Maarri, H. Singer, H.-H. Brackmann, J. Schröder, J. Graw, C. R. Müller, W. Schramm, R. Schwaab, P. Hanfland, J. Oldenburg

V..Pediatric Hemostaseology

16. Effects of the Factor V G1691 A Mutation and the Factor II G20210A Variant on the Clinical Expression of Severe Hemophilia A (< 2%) in Children — Results of a Multicenter Study
K. Kurnik, C. Escuriola-Ettingshausen, S. Horneff, C. Düring, R. Schobess, C. Bidlingmaier, S. Halimeh, H. Pollmann, N. Bogdanova, U. Nowak-Göttl

17. Continuous Infusion of Factor Concentrates in Children with Hemophilia A in Comparison to Bolus Injections
C. Bidlingmaier, M. Deml, K. Kurnik

18. Decreased Clotting Factor Activity (VIII, IX, XI, and XII) due to Inhibitors with Lupus-like Activity in Childhood
V. Aumann, L. Wiens, G. Lutze, U. Mittler

VI..Free Lectures

19. Effect of Activated Recombinant Coagulation Factor VII on the Function of Glycoprotein IIb/IIIa-Inhibited Platelets in Vitro
M. Udvardy

20. Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema
T. Förster, A. Kocot, J. Schröder, W. Kreuz, E. Aygören-Pürsün, I. Martinez-Saguer, K. Bork, I. Scharrer, C. Müller, J. Oldenburg

21. Recurrent Mutation in ADAMTS13 Gene as a Cause of a Hereditary Thrombotic Thrombocytopenic Purpura in the Czech Republic
I. Hrachovinová, P. Salaj, J. Suttnar, Š. Rittich, P. Jinoch, T. Šuláková, J. Pták, P. Dulícek, T. Seeman

22. Clinical Manifestations of Patients with Dysfibrinogenemia
W. Miesbach, V. Catania, M. Boehm, Th. Vigh, I. Scharrer

23. Case Report of a FXIII Inhibitor in a 77-year-old Patient
W. Miesbach, M. Boehm, Ch. Auer, I. Scharrer

VII..Poster

24. The ABC’s of Hemophilia
25. The Long Journey to Being Diagnosed as a Carrier of Hemophilia A — A Woman with Abnormally Prolonged Bleeding after Myocardial Infarction
W. Miesbach, B. Putz, Ch. Auer, I. Scharrer

26. Clinical Investigation of Orthopedic Outcome in Patients with Severe Hemophilia — Advantage of an Early Prophylactic Treatment?
S. Meister, K. Christensen, A. Weidenhammer, T. Spranger, G. Auerswald

27. The Relevance of Thrombophilic Risk Factors on Bleeding Tendency in Hemophilia A Patients
M. Krause, A. Hahn, F. Peyvandi, I. Scharrer

28. Magnetic Field Therapy in Patients with Severe Hemophilia — Motion Analysis and Quality Control
A. Seuser, G. Schumpe, T. Wallny, H.-H. Brackmann

29. The Clinical Course of two Patients Receiving High Dose Factor VIII — Replacement Therapy
K. H. Beck, M. Mohrmann

30. Determination of the Factor VIII Plasma Activity of Hemophilia A Patients Treated with a New Recombinant Factor VIII Concentrate
K.-W. Pape, R. Klamroth, U. Kyank, J. Bohner

31. Socio-Economic Aspects of Hemophilia Treatment in Romania
D. Mihailov, M. Serban, B. Lippert, W. Schramm, S. Arghirescu

32. Immunosuppressive Treatment in Acquired von-Willebrand’s Syndrome
H.-H. Wolf, A. Harba, A. Frühauf, H.-J. Schmoll

33. HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Medical Aspects
H. Krebs, M. M. Schneider, W. Schramm

34. HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Psychosocial Aspects
M. M. Schneider, H. Krebs, W. Schramm

35. Testing Factor VIII Activity by Using the Chromogenic Assay in Carriers of Hemophilia A
W. Miesbach, Th. Vigh, I. Scharrer

36. Hip Replacement in Hemophilic Patients — A 30 Years Single Center Experience
A. Kurth, Ch. Eberhardt, L. Hovy, M. Krause, I. Scharrer

37. Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII
M. Krause, Ch. Auer, I. Stier-Brück, I. Scharrer

38. Unusual Prolonged Course of an Immune Tolerance Therapy (ITT) in a Patient with Severe Hemophilia A and a High-Titer Inhibitor Development
S. Meister, T. Spranger, K. Christensen, H.-H. Brackmann, G. Auerswald

39. Successful Major Surgery with Minimal Dosage of rFVIIa in a Hemophilia A Patient with High Level of Alloantibodies to Factor VIII
M. Serban, P. Tepeneu, S. Arghirescu, R. Badeti, C. Jinca, D. Mihailov, D. Lighezan, W. Schramm

40. Inhibitor Development after Continuous Infusion of Factor VIII: A Retrospective Study in Germany
Ch. Auer, J. Oldenburg, M. Krause, W. Miesbach, I. Scharrer

41. Inhibitors in PTP’S: A Retrospective Study in Germany
Ch. Auer, J. Oldenburg, M. Krause, W. Miesbach, I. Scharrer

42. Elective Orthopedic Surgery in Inhibitor Patients — the Frankfurt Concept
A. Kurth, U. Stumpf, B. Habermann, M. Krause, I. Scharrer

43. The Frequency of Venous Thromboembolism in Women with FV Leiden in Association with Pregnancy and Puerperium
P. Dulícek, J. Malý, M. Pecka, M. Beránek

44. Spectrum of Molecular Defects and Mutation Detection Date in Patients with Severe Hemophilia A
N. Bogdanova, A. Markoff, U. Nowak-Göttl, R. Eisert, C. Wermes, H. Pollmann, A. Todorova, A. Eigel, B. Dworniczak, J. Horst

45. Hemophilia Patients and Prothrombotic Gene Mutation
A. Hluší, V. Krcová, P. Novák, L. Slavík

46. ?A1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians
V. Ivaskevicius, E. Jusciute, M. Steffens, Ch. Geisen, P. Hanfland, Th. F. Wienker, E. Seifried, J. Oldenburg

47. A Novel Mutation (Asp36Tyr) in the Vitamin K Epoxide Reductase Complex Subunit 1 Gene (VKORC1) Causes Increased Phenprocoumon Requirement
C. Geisen, G. Spohn, K. Sittinger, S. Rost, M. Watzka, P. Lages, A. Huth-Kühne, R. Zimmermann, C. R. Müller, E. Seifried, J. Oldenburg

48. Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene
A. Pavlova, O. El-Maarri, B. Luxembourg, E. Lindhoff-Last, D. Delev, M. Watzka, E. Seifried, J. Oldenburg

49. Recurrent Coronary Stent Thrombosis in a Patient with Combined Aspirin and Clopidogrel Resistance
Ch. Templin, A. Schaefer, B. Stumme, H. Drexler, M. Depka Prondzinski

50. Coagulation Factor XIII Mutation Profile: Update 2004
V. Ivaskevicius, R. Seitz, H.-H. Brackmann, W. Eberl, K. Kurnik, W. Kreuz, R. Klamroth, H. Rott, R. M. Loreth, F. Herrmann, E. Seifried, J. Oldenburg

51. Site-Directed Mutagenesis of VKORC1, the Target Protein of Coumarin-Type Anticoagulants
S. Rost, A. Fregin, M. Hünerberg, C. R. Müller, J. Oldenburg

52. Treatment of Dilution Coagulopathy by Fibrinogen and Platelet Concentrates
C. Lorenzo, M. Spannagl, B. Heindl

53. Pathogenesis of Hepatic Veno-Occlusive Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation
M. Dávid, O. Tóth, Á. Nagy, B. Meng, J. Tábori, H. Losonczy

DRM-restrictions

Printing: not available
Clipboard copying: not available

Keywords: MEDICAL / Public Health MED078000